GlassScriptPhysician profile
Anas Al-Sheikh
NPI 1902249766
$4,364.82
in general payments reported to CMS, 2019-2025
28 companies · $645 in 2025
The $645 reported for 2025 was more than what 78% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $553 · 2020: $532 · 2021: $670 · 2022: $686 · 2023: $639 · 2024: $641 · 2025: $645.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,925.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,924.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $880.86 | 2019-2025 | Evenity, Prolia, Repatha |
| Novo Nordisk INC | $464.04 | 2020-2025 | Ozempic, Rybelsus, Wegovy |
| Bayer Healthcare Pharmaceuticals INC. | $423.59 | 2021-2025 | |
| Pfizer INC. | $342.22 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $324.21 | 2019-2022 | |
| Lilly USA, LLC | $296.51 | 2020-2025 | Mounjaro, Zepbound, Jardiance |
| Amarin Pharma, INC. | $229.80 | 2020-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $223.07 | 2020-2025 | Jardiance |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $220.38 | 2021-2025 | Xifaxan |
| Sumitomo Pharma America, INC. | $124.74 | 2024-2025 | Gemtesa |
| Exact Sciences Corporation | $116.41 | 2023-2025 | Cologuard Collection Kit |
| Otsuka America Pharmaceutical, INC. | $113.71 | 2023-2025 | Rexulti, Nuedexta |
| Acadia Pharmaceuticals INC | $78.50 | 2022-2023 | Nuplazid |
| Glaxosmithkline, LLC. | $77.59 | 2020-2024 | Arexvy, Trelegy Ellipta, Shingrix |
| Boston Scientific Corporation | $62.47 | 2023-2024 | Watchman Flx |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Paratek Pharmaceuticals, INC. | $51.99 | 2024-2025 | Nuzyra |
| Biohaven Pharmaceutical Holding Company LTD. | $51.40 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $49.68 | 2022-2023 | Austedo, Austedo Xr |
| Novartis Pharmaceuticals Corporation | $44.08 | 2022-2023 | |
| Biohaven Pharmaceuticals, INC. | $37.02 | 2020-2021 | |
| Radius Health, INC. | $26.27 | 2019-2020 | |
| Corcept Therapeutics | $24.07 | 2025 | Korlym |
| Lundbeck LLC | $21.56 | 2023 | Rexulti |
| Dexcom, INC. | $19.50 | 2024 | Dexcom G6 Transmitter |
| Abbvie INC. | $17.30 | 2022 | |
| Sunovion Pharmaceuticals INC. | $16.62 | 2019 | |
| Abbott Laboratories | $15.06 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $12.17 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anas Al-Sheikh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.